TRGT
Targacept Inc
Clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) modulators to treat central nervous system diseases and disorders
CUSIP: 87611R306HealthcareUS1 holder
Targacept Inc
Clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) modulators to treat central nervous system diseases and disorders
No insider transactions reported in the last 6 months. Look across all recorded history →